The first clinical scenario described a patient with human epidermal growth factor receptor 2 positive (HER2+) breast cancer who experienced an asymptomatic decline in left ventricular ejection fraction (LVEF) (55 to 33%) while receiving trastuzumab. Here, ERBB2 is linked to breast carcinoma.